ArticleBMC cancer2025
Analysis of age-related survival differences in advanced non-small cell lung cancer patients based on real-world data.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgery Versus Radiation for Stage 1A NSCLC in Nonagenarians: 20 Years of Data, Decisions, and Outcomes.Annals of surgical oncology · 2026Article
- The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates survival differences between elderly and younger patients with advanced non-small cell lung cancer and their relationship with multimodal treatments, aiming to inform clinical decision-making.
methodsWe retrospectively analyzed clinical data from 590 patients diagnosed with advanced non-small cell lung cancer between 2018 and 2024. Data included demographics, tumor characteristics, and survival outcomes. Propensity score matching was used to balance baseline characteristics, and Kaplan-Meier curves and multivariate Cox regression models assessed survival differences.
resultsAfter propensity score matching, no significant baseline differences were observed. Kaplan-Meier analysis showed median overall survival of 21 months for the ≥ 70 years group and 19 months for the < 70 years group (HR = 0.941, 95% CI 0.766-1.156, P = 0.555). Median cancer-specific survival was 21 months for the ≥ 70 years group and 17 months for the < 70 years group (HR = 0.892, 95% CI 0.716-1.112, P = 0.298). Cox regression analyses revealed that age was not an independent prognostic factor for survival. Subgroup analysis indicated potential heterogeneity in the lung metastasis subgroup (P = 0.047), but no significant interaction effects were found in other subgroups.
conclusionElderly patients with advanced non-small cell lung cancer achieve comparable survival benefits to younger patients when treated with multimodal approaches. Age is not an independent prognostic factor. These findings support multimodal treatment strategies for elderly patients and highlight the need for further research into personalized treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.